In addition, the study also found that lung cancer patients with high levels of FGL1 in plasma have relatively poor therapeutic effects of PD-1 inhibitors, suggesting an underlying association between the FGL1/LAG-3 and PD-1/PD-L1 immunotherapy resistance. This evidence concerns the gene FGL1 and lung cancer.